Pfizer's deal with the Sanford-Burnham Medical Research Institute to identify and validate new drug targets to prevent and treat insulin resistance and organ damage in obesity-related diabetes could help reverse a trend that has seen the pharma arriving late-or not at all-to the party with new targets for the indication.